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ABSTRACT
Purpose: The previously reported Japanese clinical scoring study (JESREC) suggests that
chronic rhinosinusitis (CRS) can be divided into 4 subtypes according to the degree of
eosinophilic CRS (ECRS) and offers the information regarding the prognosis of CRS to
clinicians. However, this scoring system has not yet been validated by an immunological
study and needs to provide treatment guidelines based on underlying immunologic profiles.
We investigated the immunologic profile of each CRS subgroup according to the JESREC
classification and suggest its clinical application.
Methods: A total of 140 CRS patients and 20 control subjects were enrolled. All patients were
classified into 4 groups according to the JESREC (non-, mild, moderate and severe ECRS).
Nasal tissues were analyzed for mRNA expression of major cytokines (IL-5, IL-10, IL-13, IL17A, IL-22, IL-23p19, IFN-γ, periostin, thymic stromal lymphopoietin [TSLP] and ST2), major
chemokines (CCL11, CCL24, CXCL1 and CXCL2), transcription factors (T-bet, GATA3, RORC
and FOXP3) and COL1A1 for type I collagen. Protein levels of 3 major cytokines (IL-5, IL-17A
and IFN-γ) were also measured by multiplex immunoassay. Principal component analysis
(PCA) was conducted to investigate the overall profile of multiple mediators.
Results: The moderate/severe ECRS showed up-regulation of type 2-related mediators (IL-5,
IL-13, periostin, TSLP and ST-2), whereas INF-γ (type 1 cytokine) and CXCL1 (neutrophil
chemokine) expressions were increased in non-/mild ECRS compared with moderate/severe
ECRS. The JESREC classification reflected an immunological endotype. In PCA data, PCA1
indicates a relative type 2 profile, whereas PCA2 represents a type 1/type 17-related profile. In
this analysis, mild ECRS was indistinguishable from non-ECRS, whereas moderate to severe
ECRS showed a distinct distribution compared with non-ECRS. The JESREC classification
could be divided into 2 categories, non-/mild vs. moderate/severe ECRS based on underlying
immunological analyses.
Conclusions: The CRS clinical scoring system from the JESREC study reflects an inflammatory
endotype. However, the immunologic profile of mild ECRS was similar to that of non-ECRS.
Therefore, we propose type 2-targeted medical treatment for moderate to severe ECRS and
type 1/type 17-targeted for non-ECRS and mild ECRS as the first treatment option.
Keywords: Nasal polyps; rhinitis; sinusitis; validation studies; therapeutics; physicians
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INTRODUCTION
Chronic rhinosinusitis (CRS) is a common chronic inflammatory disease of the nasal and
paranasal mucosa.1 It usually causes substantially impaired quality of life, reduces workplace
productivity and is related to substantial direct and indirect economic cost.2 CRS is currently
defined as subgroups of patients based on nasal endoscopic findings, either with nasal
polyps (CRSwNP) or without nasal polyps (CRSsNP).1 Endoscopic sinus surgery (ESS) is an
effective intervention for patients with medically recalcitrant CRS. However, although ESS
has been performed appropriately, some patients show symptom persistence and disease
recurrence, or often need revision surgeries.3-5 Therefore, clinicians have been interested in
the development of biomarkers to determine which CRS patients would recur after ESS.
In the past, CRS was thought to be a dichotomous disease according to the clinical phenotype
(CRSsNP and CRSwNP),6-8 but the concept has recently changed to the disease continuum
that has a broad inflammatory spectrum.9-12 Thus, to date, the inflammatory endotype is
more useful to determine the clinical course and therapeutic decision on CRS patients.
However, only a few endotyping systems that clinicians can use in their clinics have been
suggested, because most of the endotyping systems require an invasive procedure to harvest
nasal tissues and complicated bench works.
Recently, a Japanese group developed a novel clinical scoring system for CRS, called the
JESREC scoring system, based on a large number of CRS patients (1,716).5 According to
this system, clinicians can classify CRS patients into non-ECRS (eosinophilic CRS), mild
ECRS, moderate ECRS and severe ECRS based on clinical parameters including CT findings
and blood eosinophilia. These subgroups showed a significant correlation with both the
recurrence and refractoriness. Moreover, clinicians can easily use this scoring system using
nasal endoscopic exam, peripheral blood sampling, sinus CT findings, and history of
bronchial asthma and aspirin/nonsteroidal anti-inflammatory drug (NSAID) intolerance. It
is notable that this algorithm could give useful information to clinicians for predicting the
refractoriness of CRS without a complicated endotyping process. However, the molecular
inflammatory profile of the JESREC scoring system has not yet been established. Given that
two-track treatment strategy (type 2 vs. type 1/type 17) has been suggested in CRS, 4 subtypes
of CRS from JESREC study need to be simplified into 2 subtypes. Therefore, in the present
study, we investigated whether the JESREC scoring system is relevant to the molecular
inflammatory profiles and suggested a new medical treatment strategy for CRS including
emerging biologic agents.

MATERIALS AND METHODS
Subjects
Sinonasal tissues were obtained from patients with CRS during routine ESS. The diagnosis
of CRS was based on personal medical history, physical examination, nasal endoscopy and
CT findings of the nasal cavity with sinuses according to the 2012 European position paper
on rhinosinusitis and nasal polyps (EPOS) guidelines.1 Patient exclusion criteria were as
follows: 1) younger than 18 years old; 2) previous treatment with antibiotics, systemic or
topical corticosteroids, or other immune-modulating drugs up to 4 weeks before surgery;
and 3) conditions such as unilateral rhinosinusitis, antrochoanal polyps, allergic fungal
sinusitis, cystic fibrosis or immotile ciliary disease. Control tissues were obtained during
https://e-aair.org

https://doi.org/10.4168/aair.2018.10.5.490

491

Novel Treatment Strategy for Chronic Rhinosinusitis

other rhinologic surgeries such as skull base, lacrimal duct or orbital decompression surgery
and from patients without any sinonasal diseases. We obtained uncinate tissue from control
and CRS patients. We also took NP tissues in CRSwNP patients. All enrolled patients
were classified into subgroups according to the algorithm of JESREC study5: control,
non-eosinophilic CRS (non-ECRS), mild eosinophilic chronic rhinosinusitis (ECRS),
moderate ECRS and severe ECRS. Subgrouping is conducted by several clinical factors
including bilateral disease sites, NP, sinus CT findings, eosinophilia in peripheral blood
and comorbidity (bronchial asthma and aspirin-exacerbated respiratory disease/NSAIDexacerbated respiratory disease). Meanwhile, histological eosinophilic CRS was defined
as > 10% eosinophils per high-power field (HPF).13 All patients provided a written form of
informed consent for study participation, and this study was approved by the Institutional
Review Board of Seoul Metropolitan Government-Seoul National University Boramae
Medical Center.

Quantitative real-time RT-PCR
We analyzed the mRNA expression levels of cytokines (IL-5, IL-10, IL-13, IL-17A,
IL-22, IL-23p19, IFN-γ, periostin, thymic stromal lymphopoietin [TSLP], ST2 and
TGF β2), inflammatory markers (CCL11, CCL24, CXCL1, CXCL2 and COL1A1) and
major transcription factors (GATA-3, RORC, T-bet and FOXP-3) by quantitative realtime PCR (qRT-PCR). Total RNA was extracted from tissue samples with TRI reagent
(Invitrogen, Carlsbad, CA, USA). One microgram of total RNA was reverse-transcribed
to cDNA with a cDNA Synthesis Kit (amfiRivert Platinum cDNA Synthesis Master Mix,
GenDEPOT, Barker, TX, USA). The qRT-PCR was performed with a LightCycler 480
SYBR Green I Master (Roche, Mannheim, Germany). For analysis of IL-5 (Hs01548712_
g1), IL-10 (Hs00961622_m1), IL-13 (Hs00174379_m1), IL-17A (Hs00174383_m1),
IL-22 (Hs01574154_m1), IL-23p19 (Hs00900828_g1), IFN-γ (Hs00989291_m1),
periostin (Hs01566734_m1), TSLP (Hs00263639_m1), ST2 (Hs00545033_M1),
CCL11 (Hs00237013_m1), CCL24 (Hs00171082_m1), CXCL1 (Hs00236937_m1),
CXCL2 (Hs00601975_m1), and GAPDH (Hs02758991_g1), pre-developed assay
reagent (PDAR) kits of primers and probes were purchased from TaqMan assays (Life
Technologies Korea, Seoul, Korea). COL1A1 (QT00037793) was also purchased from
QIAGEN Korea Ltd. (Seoul, Korea). Also, the quantitative real-time PCR assay was
performed with appropriate primers that specifically amplified T-bet, GATA-3, RORC,
FOXP3and TGF β2. Primers were as follows: T-bet, 5′-GTCAATTCCTTGGGGGAGAT-3′
for the forward primer and 5′-TCATGCTGACTGCTCGAAAC-3′ for the
reverse primer; GATA-3, 5′-ACCACAACCACACTCTGGAGGA-3′ for the
forward primer and 5′-TCGGTTTCTGGTCTGGATGCCT-3′ for the reverse
primer; RORC, 5′-GCTGTGATCTTGCCCAGAACC-3′ for the forward
primer and 5′-CTGCCCATCATTGCTGTTAATCC-3′ for the reverse primer;
FOXP3, 5′-ACAGTCTCTGGAGCAGCAGC-3′ for the forward primer and
5′-CCACAGATGAAGCCTTGGTC-3′ for the reverse primer; and TGF
β2, 5′-TGGATGCGGCCTATTGCTTTA-3′ for the forward primer and
5′-GCGGAAGTCAATGTACAGCTGCCGC-3′ for the reverse primer, and
GAPDH, 5′-CATGGGTGTGAACCATGAGAA-3′ for the forward primer,
5′-GGTCATGAGTCCTTCCACGAT-3′ for the reverse primer. GAPDH was measured as a
housekeeping gene for normalization. Cycling conditions were 95°C for 5 minutes, followed
by 60 cycles at 95°C for 15 seconds, 55°C for 20 seconds, and 72°C for 20 seconds. Data were
analyzed with Sequence Detection Software version 1.9.1 (Applied Biosystems, Foster City,
CA, USA). Relative gene expression was calculated by the comparative 2-ΔΔCT method.
https://e-aair.org
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Measurement of major cytokines
The protein concentrations for tissue extracts were determined using the Pierce 660
nm Protein Assay Kit (ThermoScientific Inc., NY, USA). All the protein levels in tissue
homogenate were normalized to the concentration of total protein (mg/mL). Samples were
thawed at room temperature and vortexed to ensure well-mixed sample. Cytokine analysis
kits (IL-5, IL-17A and IFN-γ) were obtained from R&D systems (Cat. No. LMSAHM) and data
were collected using Luminex 100 (Luminex, Austin, TX, USA). Data analysis was performed
using the MasterPlex QT version 2.0 (MiraiBio, Alameda, CA, USA). Sensitivity of each
cytokine is as follows: IL-5 (0.5 pg/mL), IL-17A (1.8 pg/mL) and IFN-γ (0.4 pg/mL). All assays
were run in duplicate according to the manufacturers' protocol.

Statistical analysis
Statistical analyses were performed using IBM SPSS 20 (SPSS, Inc., Chicago, IL, USA) and
GraphPad Prism software 6.0 (GraphPad Software Inc., La Jolla, CA, USA). For comparisons
among more than 2 groups, the Kruskal-Wallis test was initially used to identify the significant
difference, and then, the Mann-Whitney U test was also executed to confirm significance
between 2 groups. For adjustment the significance level for each comparison, Bonferroni
adjustment was used. A multivariate analysis of data for mRNA expression levels was conducted
using principal component analysis (PCA). The significance level was set at α = 0.05 (*P < 0.05,
†
P < 0.01, and ‡P < 0.001).

RESULTS
Characteristics of the study population
We enrolled total 140 CRS patients and 20 control subjects. Demographic and clinical
characteristics of the enrolled subjects in this study are presented in Table. According to
the JESREC scoring system, the proportion of each subgroup was as follows: non-ECRS,
50.7% (n = 71); mild ECRS, 17.1% (n = 24); moderate ECRS, 23.6% (n = 33); and severe ECRS,
8.6% (n = 12). There was no significant difference in Lund-Mackay CT score or the presence
of atopy/nasal polyp among 4 groups. The ratio of histological eosinophilic CRS increased
consistently with the progression from clinical non-ECRS to severe ECRS based on the
JESREC system. In non-ECRS, 23.9% patients were confirmed with histologic eosinophilic
CRS. Mild, moderate and severe ECRS groups had 45.8%, 61.3% and 71.4% of histologic
eosinophilic CRS, respectively.

Table. Patient characteristics and type of method
Total No. of subjects
Control (n = 20)
Non-ECRS (n = 71)
Mild ECRS (n = 24)
Moderate ECRS (n = 33)
Severe ECRS (n = 12)
Age (yr), mean (SD)
45 (19)
49 (15)
47 (14)
46 (14)
52 (13)
Sex (male), No. (%)
14 (70)
46 (64.8)
22 (91.7)
24 (72.7)
5 (41.7)
Asthma, No. (%)
0 (0)
2 (2.8)
0 (0)
3 (9.1)
12 (100)
Atopy, No. (%)
5 (25)
21 (29.6)
10 (41.7)
16 (48.5)
5 (41.7)
Aspirin sensitivity, No.
0
0
0
0
2
Lund-Mackay CT score
0 (0)
12.7 (6.1)
14.5 (4.3)
13.2 (5.2)
16.8 (6.6)
Blood eosinophil % (SD)
2.28 (1.12)
2.43 (1.72)
4.59 (2.09)
7.61 (2.75)
10.6 (4.11)
CRSsNP, No. (%)
0
37 (52.1)
5 (20.8)
16 (48.5)
4 (33.3)
CRSwNP, No. (%)
0
34 (47.9)
19 (79.2)
17 (51.5)
8 (66.7)
Histologic eosinophilic CRS, No. (%)
0
16 (23.9)
11 (45.8)
19 (61.3)
10 (83.3)
ECRS, eosinophilic chronic rhinosinusitis; SD, standard deviation; CT, computed tomography; CRSsNP, chronic rhinosinusitis without nasal polyps.
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Expression of inflammatory cytokines and chemokines according to different
CRS groups
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Relative IL-13 mRNA expression

Relative IL-5 mRNA expression

To investigate the immunological profile, we performed qRT-PCR analysis on sinonasal
tissues (UP from control, CRSsNP and NP from CRSwNP). Besides, type 2-associated
cytokine profiles including IL-5, IL-13, periostin, TSLP, ST-2 (receptor for IL-33) and
CCL24 showed an up-regulated expression tendency from control to severe ECRS (Fig. 1).
Meanwhile, type 17-related cytokines such as IL-17A, IL-22 and IL-23p19 mRNA expression
showed a significant upregulation in non-ECRS and mild ECRS or moderate ECRS than
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Fig. 1. Expression of type 2-related cytokines in nasal tissues according to clinical CRS classification.
CRS, chronic rhinosinusitis; ECRS, eosinophilic chronic rhinosinusitis; IL, interleukin; TSLP, thymic stromal lymphopoietin.
*P < 0.05, †P < 0.01, and ‡P < 0.001.
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controls and severe ECRS. CXCL1, a neutrophils-recruiting chemokine, was overexpressed
in non-ECRS and mild ECRS compared with moderate ECRS. Additionally, type 1 cytokine,
INF-γ mRNA expression was significantly more decreased in moderate and severe ECRS
groups compared with control subjects and non-ECRS group (Fig. 2). An anti-inflammatory
cytokine, IL-10, demonstrated increasing tendency towards severe ECRS. We also evaluated
the protein levels of cytokine profiles (IL-5, IL-17A and IFN-γ) in different CRS groups.
Expression levels of IL-5 was signiﬁcantly increased from controls to severe ECRS, whereas
†
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Relative IL-17A mRNA expression
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Fig. 2. Expression of type 1- or type 17-related cytokines in nasal tissues according to clinical CRS classification.
CRS, chronic rhinosinusitis; IL, interleukin; ECRS, eosinophilic chronic rhinosinusitis.
*P < 0.05, †P < 0.01, and ‡P < 0.001.
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IL-17A and IFN-γ were significantly more decreased in severe ECRS groups compared with
non- and mild ECRS groups (Fig. 3).

Expression of tissue remodeling mediators and transcription factors
according to different CRS groups
In the analysis of tissue remodeling mediators, there was no difference in the expression of
COL1A1 mRNA levels among CRS groups. However, the expression of TGF-β2 mRNA levels
was significantly more increased in non-ECRS and mild ECRS, compared with controls
(P = 0.0011 and P = 0.0108, respectively). We also found that the GATA-3 levels were
significantly less expressed in non-ECRS and mild ECRS groups than in controls, whereas
these groups showed a significantly more increased expression of T-bet levels compared with
controls (Fig. 4). However, there were no differences in the levels of RORC or FOXP3.

Principal component analysis (PCA)
To investigate the overall immunologic profile according to the different CRS groups, we
performed the PCA (Fig. 5). The first component (PCA1) accounted for 15.9% of the variance
in the dataset, and its greater discriminators were IL-10, TSLP, IL-13 and CCL24 (in order).
The second component (PCA2) accounted for 14.4% of the variance in the dataset, and its
greater discriminators were CXCL1, IFN-γ and IL-17A (in order). Thus, the PCA1 component
represented a predominant type 2-related immunologic profile, whereas PCA2 component
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Fig. 3. Expression of IL-5, IL-17A and IFN-γ in nasal tissues according to clinical CRS classification.
IL, interleukin; CRS, chronic rhinosinusitis; ECRS, eosinophilic chronic rhinosinusitis.
*P < 0.05, †P < 0.01, and ‡P < 0.001.
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Fig. 4. Expression of transcription factors in nasal tissues according to clinical CRS classification.
CRS, chronic rhinosinusitis; ECRS, eosinophilic chronic rhinosinusitis.
*P < 0.05.

indicated a relative type 1/type 17-related immunologic profile. This PCA data revealed that
PCA1 and PCA2 could help discriminate between non-/mild ECRS and moderate/severe
ECRS. Moreover, we found that moderate and severe ECRS groups showed a high type
2 and low type 1/type 17-related expression, whereas mild and non-ECRS have a similar
immunologic profile with high type 1/type 17 and low type 2-related expression.
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2
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0

Severe ECRS
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0

2

4

6

8

PCA1 (15.9%)
Fig. 5. PCA consisted of the first and second PCA components using multiple inflammatory mediators according
to clinical CRS classification.
PCA, principal component analysis; CRS, chronic rhinosinusitis; ECRS, eosinophilic chronic rhinosinusitis.

https://e-aair.org

https://doi.org/10.4168/aair.2018.10.5.490

497

Novel Treatment Strategy for Chronic Rhinosinusitis

Non-ECRS

Mild ECRS

Type 1/Type 17
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No
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No

Type 2
targeted
No

Surgery

Severe ECRS

No

Fig. 6. Clinical therapeutic strategy for CRS according to clinical CRS classification.
CRS, chronic rhinosinusitis; ECRS, eosinophilic chronic rhinosinusitis.

DISCUSSION
To date, intranasal or systemic steroids, antibiotics and nasal irrigation are considered a main
treatment for patients with CRS.1,14 Besides these, aspirin desensitization has been used as
an adjunctive treatment in patients with CRSwNP who have aspirin-exacerbated respiratory
disease.15-17 Sometimes, CRS patients who have a medically refractory condition underwent
ESS to improve mucociliary clearance and restore patency of sinus drainage tracts. However,
despite the advance in surgical techniques and the use of intranasal steroids after ESS, some
patients suffer from recurrence of their disease. This indicates that there is an extreme
diversity on CRS regarding the immunologic endotypes. Thus, novel therapeutics are needed
to treat these medically and/or surgically refractory CRS patients.
Currently, several studies from Western counties have been suggested that there are
distinct immunologic mechanisms in patients with CRSsNP (predominant type 1 milieu)
and CRSwNP (type 2-skewed eosinophilic inflammation).6-9 Meanwhile, the inflammatory
endotype of Asian subjects is primarily dominant neutrophilic inflammation with type 1/
type 17 immune response, but this endotype is minority in Western.10-12 Moreover, a cluster
analysis study with phenotype-free approach has identified that CRS patients have 10 distinct
inflammatory endotypes, which are correlated with phenotype and that these endotypes
comprise 4 clusters with low IL-5 and 6 clusters with moderate to high IL-5.18 Another cluster
analysis study also suggested 7 CRS clusters according to the immunologic characteristics
and treatment outcomes.19 These indicate that CRS shows remarkable heterogeneity at the
molecular level and that the characteristics of each endotypes may have a serial continuum of
immunologic profile.
However, NP tissues also frequently recur after surgery in Asian CRSwNP, and patients with
these recurrent NP show prominent tissue eosinophilic infiltration.20 Some studies from
Japan showed that CRSwNP patients with ≥ 70 eosinophils/HPF had the highest recurrence
rate compared to other groups with lower tissue eosinophilia.21,22 Thus, consistent with
Western NP, tissue eosinophilic status can provide information regarding prognosis of
CRSwNP in Asian populations. However, there is still no clear consensus about the criteria
of ECRS. In addition, the lab-based methods using ECP/MPO ratio or periostin, has not been
validated as a single useful predictable biomarker.
Recently, the novel classification system of CRS was suggested by a Japanese group through
multi-center studies.5 This classification named the JESREC scoring system may be used as a
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tool that can easily predict clinical course. The major advantage of the JESREC scoring system
is that it can be easily measured with clinically available parameters. The sinus CT scan,
eosinophil count of peripheral blood and nasal endoscopy are sufficient to diagnose ECRS,
and only a history of asthma or aspirin intolerance is additionally needed for 4 subgroupings
of ECRS. Thus, the JESREC scoring system enables clinicians to classify ECRS without any
invasive procedure such as biopsy or surgery. In addition, these 4 groups are well correlated
with the rate of recurrence and refractoriness in CRS. Among those, moderate and severe
ECRS groups are considered as refractory CRS.
Despite these advantages, the JESREC scoring system still need a verification to be used as a
diagnostic tool of CRS, because it has relatively low specificity (sensitivity: 83%, specificity:
66%) for discrimination between non-ECRS and ECRS. It means a significant number of
immunologic non-ECRS patients may be included in the ECRS group. Thus, in the present
study, we investigated and compared the immunologic profile according to the JESREC
classification. In accordance with the findings of previous studies,6-12 the present study
confirmed that there were significant differences in the inflammatory profile of the 4 CRS
subgroups classified by the JESREC scoring system. Specifically, moderate and severe ECRS
is related to IL-5, IL-13, periostin, TSLP and ST-2, representing type 2 cytokines, whereas
non-ECRS relates to type 1/type 17-associated cytokines. From our analysis, mild ECRS was
immunologically similar to non-ECRS, which is attributed to the relatively low specificity
of the JESREC classification system. Furthermore, in contrast with previous studies,23-25 we
observed that the level of IFN-γ as a type 1 cytokine was not increased in non-ECRS and mild
ECRS patients, compared with control subjects. We thought that this discrepancy may be
caused by using different nasal tissues for the evaluation of IFN-γ between prior studies and
our study. The prior studies have used inferior turbinate or ethmoidal mucosa as controls,
whereas we used UP tissues.26 In addition, a recent study supported our findings and it also
similarly described the IFN-γ expression, which did not significantly elevate in CRSsNP.27
To date, the concept of personalized treatment of CRS is based on its endotypes, because
CRS shows highly heterogeneity which causes different therapeutic responses.25,28 However,
the current therapeutic strategy for CRS has roughly 2 treatment approaches. One approach
is the use of intranasal/systemic corticosteroids in ECRS patients treated with medical
management alone or surgery plus medical management.29-31 Several studies have revealed
that CRS patients with a higher expression of type 2-cytokines (IL-5 high and IL-13 high)
tend to shows a better clinical benefit from corticosteroids.32,33 In this condition, physicians
could also consider the use of biologics (type 2 targeted) for treatment of ECRS. Other
approach for non-ECRS patients is intranasal corticosteroid plus antibiotic therapy followed
by surgery.34,35 As with asthma, it is recognized that non-ECRS show a steroid-resistant
phenotype. Thus, type 2 biologics would be ineffective in these patients. Interestingly, our
PCA findings revealed that mild ECRS patients showed more similar inflammatory patterns
to non-ECRS patients rather than moderate or severe ECRS. In addition, moderate and severe
ECRS patients have similar inflammatory patterns on PCA findings. Thus, we propose the
2-track treatment strategy (Fig. 6). Moderate and severe ECRS patients are treated by type
2-targeted medication, such as systemic corticosteroids or anti-eosinophilic or anti-type 2
biologic agents. On the other hand, non-ECRS and mild ECRS patients are managed with
sufficient antibiotic therapy including a long-term macrolide, followed by surgery or newly
emerging anti-type 17 biologic agents. Meanwhile, type 2-targeted therapy could also be tried
in some mild ECRS patients when antibiotics were not effective, because a part of mild ECRS
may belong to a type 2 inflammatory category (Fig. 6). However, the long-term results of the
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2-track treatment strategy have not been obtained yet. Therefore, further studies are needed
to establish the consensus of the 2-track treatment strategy on CRS patients.
In conclusion, the JESREC clinical CRS classification system well reflects immunologic
characteristics of CRS patients. Based on this classification, we propose a 2-track treatment
strategy for CRS patients. Although our findings have no long-term prognosis after treatment
according to the clinical CRS classification, this strategy might help clinicians make a better
decision to treat individual CRS patients based on clinical parameters without tissue-based
inflammatory endotyping.
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